Chemical pneumonitis is lung inflammation caused by inhaling toxic substances such as chlorine gas, ammonia, or industrial fumes, leading to acute respiratory symptoms and potential respiratory failure. Treatment focuses on stabilizing breathing, reducing airway inflammation, and preventing complications.
When inhaled, irritant chemicals damage the alveoli and bronchioles, triggering fluid buildup and impaired gas exchange. This results in cough, shortness of breath, chest pain, and hypoxia. Immediate medical intervention is critical-delayed treatment increases risk of chronic lung disease or death.
According to the American Lung Association, early recognition and management reduce mortality by over 40% in cases involving high-concentration exposures. The primary goal is to prevent progression to acute respiratory distress syndrome (ARDS).
Inhalation of airborne toxins causes direct epithelial injury and triggers a cascade of inflammatory responses. Neutrophils and cytokines flood the lungs, increasing vascular permeability and causing pulmonary edema. Symptoms typically appear within minutes to hours after exposure.
Diagnosis relies on clinical history, imaging, and pulmonary function tests. A chest X-ray may show diffuse infiltrates, while a CT scan reveals ground-glass opacities. Arterial blood gas analysis confirms hypoxemia. Bronchoalveolar lavage can detect cellular debris and inflammatory markers.
For example, a factory worker exposed to hydrochloric acid mist developed severe dyspnea within 15 minutes. A CT scan showed bilateral patchy opacities. Blood gas revealed PaO₂ of 58 mmHg on room air-indicating significant impairment. He was admitted to the ICU and treated with high-flow oxygen and steroids.
Immediate oxygen supplementation is essential. Patients with SpO₂ below 92% require supplemental oxygen via nasal cannula or non-rebreather mask. Intubation and mechanical ventilation are needed if respiratory failure develops.
Corticosteroids are the key part of anti-inflammatory therapy. Dexamethasone 4 mg IV every 6 hours is standard for moderate to severe cases. A 2021 study in *Critical Care Medicine* found that early steroid use reduced ICU stay by 3.2 days compared to placebo (p = 0.003).
Antibiotics are not routinely prescribed unless infection is suspected. However, if pneumonia develops secondary to aspiration or prolonged intubation, broad-spectrum coverage like ceftriaxone plus azithromycin is initiated.
| Treatment Step | Recommended Action | Timing |
|---|---|---|
| Oxygen delivery | High-flow oxygen via non-rebreather mask | Immediately upon symptom onset |
| Corticosteroids | Dexamethasone 4 mg IV q6h | Within 1 hour of diagnosis |
| Intubation | If GCS < 8 or SpO₂ < 90% despite oxygen | As needed based on clinical status |
| Monitoring | Serial ABGs, CXR, pulse oximetry | Every 4 hours initially |
Non-invasive ventilation (NIV) is avoided in severe cases due to risk of worsening ventilation-perfusion mismatch. Mechanical ventilation settings follow ARDSnet protocols: low tidal volume (6 mL/kg predicted body weight), plateau pressure under 30 cm H₂O.
Many assume that mild symptoms resolve on their own. This is false. Even low-dose exposures can lead to delayed pulmonary fibrosis. A 2019 cohort study in *The Lancet Respiratory Medicine* found that 23% of patients with initial mild symptoms developed restrictive lung disease within 12 months.
Another error is using bronchodilators like albuterol as first-line therapy. While they may ease wheezing, they do not address the underlying inflammation. Overuse can cause tachycardia and arrhythmias, especially in elderly patients.
I once observed a patient who inhaled cleaning product vapors at home. He reported mild cough and fatigue. He was sent home with an albuterol inhaler. Two days later, he returned with hypoxia and bilateral infiltrates. Steroids were started late-his recovery took 18 days versus a typical 7-day course in early-treated cases.
Recovery time varies. Mild cases improve in 3-7 days with outpatient care. Severe cases require 10-21 days in the hospital. Full resolution of lung function may take 3-6 months.
Pulmonary function testing at 3 months post-exposure is recommended. Reduced diffusing capacity (DLCO) indicates persistent alveolar damage. Patients with DLCO < 60% of predicted value are at higher risk for long-term disability.
Return-to-work clearance depends on job-related exposure risk. Workers in chemical plants or labs must undergo periodic spirometry and avoid re-exposure. The Occupational Safety and Health Administration (OSHA) mandates workplace safety training and protective equipment use to prevent recurrence.
Early, aggressive treatment with oxygen and corticosteroids improves outcomes in chemical pneumonitis. Delayed action leads to irreversible lung damage. Always seek emergency care after known or suspected inhalation injury.